Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationThe Medicines and Healthcare products Regulatory Agency (MHRA), US Food and Drug Administration (FDA) and Health Canada have collaborated to identify five guiding principles for the development of predetermined change control plans (PCCPs). These guiding principles for PCCPs aim to remove the regulatory burden for developers of machine-learning-enabled medical devices (MLMDs), enabling reallocation of resources to improve product performance for patients.
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2023 meeting.
The scheme will see the lowest-risk clinical trials processed by the MHRA in less than 14 days.
A summary of the most recent EMA Committee for Veterinary Medicinal Products (CVMP) meeting.
EMA has adopted PDF icon revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System. The simplifications introduced will give access to clinical trial information to stakeholders including patients and healthcare professionals in a faster and more efficient way.
EMA Management Board: highlights of October 2023 meeting
Held 5-7 September 2023
EMA is pleased to inform you that a website has been launched for the Accelerating clinical trials in the European Union (ACT EU) initiative, co-led by the European Commission, the Heads of Medicines Agencies and the European Medicines Agency.
15 September 2023
Edition 173